The $3.95 Million Drug That Costs More Than Most Houses

The current title holder for the world's most expensive drug is Lenmeldy, a gene therapy for metachromatic leukodystrophy, priced at $4.25 million. Before that, Hemgenix (for hemophilia B) held the crown at $3.5 million. Novartis's Zolgensma, which once shocked the world at $2.125 million for spinal muscular atrophy, now looks almost quaint by comparison.

Fayuvi slots in just below Lenmeldy, making it among the most expensive drugs in the world. If you're keeping score at home, the top of the leaderboard now looks like a luxury real estate listing: every entry costs more than a beachfront condo.

Ultragenyx's rationale follows a familiar playbook: this is a one-time treatment for a fatal disease with no alternatives. The company describes the $3.95 million as a gross list price before discounts, rebates, or any outcomes-based arrangements. That "before discounts" language is doing a lot of heavy lifting, and it hints that the actual amount insurers pay could be lower. But by how much? The company hasn't said.

Wall Street's Split Verdict

Analyst reactions fell into two camps, and the divide is telling.

On the bullish side, Cantor framed Fayuvi as roughly a $325 million peak sales opportunity. Canaccord raised its price target to $39 with a Buy rating, pointing to near-term availability (the company expects U.S. shipments within 30 to 60 days of approval). The logic: ultra-rare disease, zero competition, and desperate families willing to fight for access.

Then there's the bear case. Morgan Stanley kept a Hold rating with a $20 price target, signaling skepticism that the launch can overcome the obvious hurdles. And those hurdles are real: at nearly $4 million per patient, every prescription requires a small war with insurance companies. Treatment centers need to be set up. Reimbursement pathways need to be negotiated.

The core tension is simple: pricing power means nothing if patients can't actually get the drug. A $3.95 million list price on paper is very different from $3.95 million flowing into Ultragenyx's revenue line.

The Bigger Question Nobody Wants to Answer

Fayuvi's price tag doesn't exist in a vacuum. It's a data point in a much larger, much messier debate about how society pays for genetic cures.

The traditional pharmaceutical model works on recurring payments: you take a pill every day, and your insurer pays a manageable amount each month. Gene therapies blow that model up. They deliver (in theory) a permanent fix in a single dose, but the entire cost hits at once. It's like buying a house with no mortgage; someone has to write a very large check on day one.

For ultra-rare diseases like Sanfilippo syndrome, the math can technically work because the patient population is tiny. Spreading $3.95 million across a handful of patients per year is manageable for large insurers. But as gene therapies multiply (and they are multiplying), the cumulative burden on payers grows. What happens when there are 50 approved gene therapies, each costing $2 to $4 million? The system wasn't built for this.

Outcomes-based agreements, where the company refunds some or all of the cost if the therapy doesn't work as promised, are one potential solution. Ultragenyx's pricing language leaves the door open for these deals, though no specific agreements have been announced yet. Installment payment models, where the cost is spread over several years, are another option being explored across the industry.

What Matters Now

For families affected by Sanfilippo syndrome, the price debate is almost beside the point. Their children are dying, and for the first time, there's an approved treatment that can preserve cognitive function. The label specifies pediatric patients who still have "preserved neurodevelopmental function," which means timing matters enormously. The window to treat is narrow, and every month spent arguing with insurers is a month of irreversible brain damage.

For the gene therapy sector as a whole, Fayuvi is another test case. Can companies charge near-$4 million for a one-time cure and still achieve meaningful commercial uptake? Morgan Stanley isn't so sure.

The real answer probably lies somewhere in between, in the messy, case-by-case negotiations between drugmakers and payers that happen far from the spotlight. But the spotlight is here now. And at $3.95 million per dose, it's very, very bright.

The Nobel Prize That Explains Why Your Medication Only Works One Way

The 2026 Nobel Prize in Chemistry went to two scientists who figured out how to stop molecules from being made backwards. More than half of all drugs on the market depend on this kind of chemistry, and the implications for pharma are bigger than you think.